Application of molecular biology of differentiated thyroid cancer for clinical prognostication

1. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 1

   Clinical outcome of differentiated thyroid cancer in 2 large cohorts. Data from Tuttle et al. (2010b), and Pitoia et al. (2013) (A and B, respectively).
2. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 2

   Current status of molecular characterisation of differentiated thyroid cancer.
3. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 3

   Association between BRAF^V600E and tumour-related mortality (A) and recurrence (B) in 2 large multicentre cohorts. Data from Xing et al. (2013) and Xing et al. (2015), respectively. *Significantly different at univariate analysis; **Significantly different at multivariate analysis.
4. View larger version:

   • In this window
   • In a new window

   • Download as PowerPoint Slide

   Figure 4

   Synergistic prognostic effect of co-occurrence of BRAF V600E and TERT promoter mutations in increasing the risk of tumour recurrence (ATYPESETTER: Please change “8,7%, 16,3%, 19,2%, 68,6%” to “8.7%, 16.3%, 19.2%, 68.6%” in the Figure 4. and B) and disease-related mortality (C and D) in DTC. Data from Xing et al. (2014b) (A), Xing et al. (2014a) (C), and Song et al. (2016) (B and D). †Not significantly different from the No mutations group; *Significantly different from the No mutations group; **Significantly different from the TERT promoter mutations only group; *** Significantly different from the BRAF V600E only group.

• © 2016 Society for Endocrinology